PMID- 36051497
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230728
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - Levels of Serum IGF-1, HCY, and Plasma BNP in Patients with Chronic Congestive 
      Heart Failure and Their Relationship with Cardiac Function and Short-Term 
      Prognosis.
PG  - 4118976
LID - 10.1155/2022/4118976 [doi]
LID - 4118976
AB  - OBJECTIVE: To investigate the levels of serum insulin like growth factor-1 
      (IGF-1), homocysteine (HCY), and plasma brain natriuretic peptide (BNP) in 
      patients with chronic congestive heart failure (CCHF) and their relationship with 
      cardiac function and short-term prognosis. METHODS: A total of 95 patients with 
      CCHF admitted to our hospital from October 2017 to December 2018 were selected as 
      the observation group. Patients conform to grade II approximately IV of the New York Heart 
      Association (NYHA) heart function class. At the same time, the people with normal 
      physical examination results were selected as a control group. Serum IGF-1, HCY, 
      and plasma BNP levels were detected in the two groups, and left ventricular 
      end-diastolic diameter (LVDd) and left ventricular ejection fraction (LVEF) were 
      detected in the observation group. According to the follow-up results, the 
      observation group was divided into the subgroup with good prognosis and the 
      subgroup with poor prognosis. The relationship between the levels of serum IGF-1, 
      HCY, and plasma BNP among cardiac function and short-term prognosis were 
      analyzed. RESULTS: The serum IGF-1 level of the observation group was lower than 
      that of the control group, and the serum HCY and plasma BNP levels were higher 
      than those of the control group (P < 0.05). Serum IGF-1 level in grade III of 
      NYHA was lower than that in grade II, and serum HCY and plasma BNP levels were 
      higher than those in grade II. Serum IGF-1 level in grade IV was lower than that 
      in grade II and grade III, and serum HCY and plasma BNP levels were higher than 
      those in grade II and grade III (P < 0.05). Serum IGF-1 level was negatively 
      correlated with LVDd and positively correlated with LVEF. Serum HCY and plasma 
      BNP levels were positively correlated with LVDd and negatively correlated with 
      LVEF (P < 0.05). There were 42 patients with poor prognoses (44.21%). Serum IGF-1 
      levels of patients with poor prognosis were lower than those with good prognosis, 
      and serum HCY and plasma BNP levels were higher than those with good prognosis (P 
      < 0.05). CONCLUSION: The serum IGF-1 level in patients with CCHF decreased, and 
      serum HCY and plasma BNP levels increased. Serum IGF-1, HCY, and plasma BNP were 
      correlated with cardiac function and have some clinical value for short-term 
      prognosis.
CI  - Copyright (c) 2022 Zhengyi Hu et al.
FAU - Hu, Zhengyi
AU  - Hu Z
AD  - Ethics Office, Henan Provincial Chest Hospital, Zhengzhou 450003, Henan, China.
FAU - Mao, Leifang
AU  - Mao L
AD  - Department of Rehabilitation, Henan Provincial Chest Hospital, Zhengzhou 450003, 
      Henan, China.
FAU - Wang, Ling
AU  - Wang L
AUID- ORCID: 0000-0001-5030-4596
AD  - Department of Clinical Laboratory, Henan Provincial Chest Hospital, Zhengzhou 
      450003, Henan, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20220823
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
RIN - Evid Based Complement Alternat Med. 2023 Jul 19;2023:9796373. PMID: 37501877
PMC - PMC9427243
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as potential 
      conflicts of interest.
EDAT- 2022/09/03 06:00
MHDA- 2022/09/03 06:01
PMCR- 2022/08/23
CRDT- 2022/09/02 02:32
PHST- 2022/06/09 00:00 [received]
PHST- 2022/07/21 00:00 [accepted]
PHST- 2022/09/02 02:32 [entrez]
PHST- 2022/09/03 06:00 [pubmed]
PHST- 2022/09/03 06:01 [medline]
PHST- 2022/08/23 00:00 [pmc-release]
AID - 10.1155/2022/4118976 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Aug 23;2022:4118976. doi: 
      10.1155/2022/4118976. eCollection 2022.